1Keiichi Hiramatsu MD, PhD,Noriko Kondo BSc,Teruyo Ito PhD. Genetic basis for molecular epidemiology of MRSA[J] 1996,Journal of Infection and Chemotherapy(3):117～129
2Tae Tanaka,Katsuko Okuzumi,Aikichi Iwamoto,Keiichi Hiramatsu. A retrospective study of methicillin-resistantStaphylococcus aureus clinical strains in Tokyo university hospital[J] 1995,Journal of Infection and Chemotherapy(1):40～49
2Martinez M , Lopez o Ribot JL. Heterogeneous mecha nisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis[J]. J Antimicrob Chemother, 2002,49 (3): 515-524.
3Chesneau O , Morvan A , Solh NEI . Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals[J]. J Antimicrob. Chemother, 2000,45(6):887-890.
4Susan Boyle - Vavra , Sarah KB. Reversion of the gly -copeptide resistance phenotype in Staphylococcus aureus clinical isolates[J]. Antimicrob Agents Chemother,2000,44(2) :272-277.
5Theresa L, Smith. Emergence of ancomycin resistance in Staphylococcus aureus[J]. N Engl J Med, 1999,340(7) :493-501.
6Hiramatsu K,Hanaki H,Ino T ,et al. Methicillin-resistant staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J]. J Antimicrob chemother,1997,40(1): 135-136.
7Nanae A,Hideaki H. Combination effect of vancomycin and β-lactams against a Staphylococcus aureus strain Mu3,with heterogeneous resistance to vancomycin[J].Antimicrobial Agents and Chemother, 2001, 45 (4) :1292-1294.
8Wootton M,Howe RA. A modified population analysis profile (PAP)method to vancomycin in staphylococcus aureus in a UK hospital[J]. J Antimicrob Chemother,2001,47(4) :399-403.
10Ryffel C,Strassle A. Mechanisms of heteroresistance in methicillin-resistant Staphylococcus aureus[J]. Antimicrobial Agents and Chemotherapy, 1994, 38 (4): 724-728.
